Edimer Pharmaceuticals, Inc.

Biogen Idec Ma Inc.

Université De Lausanne

Apoxis S.a.

Topotarget Switzerland Sa

Biogen Ma Inc.

Espoirxlhed Sarl

Université Grenoble Alpes

Friedrich-Alexander-Universitat Erlangen-Nürnberg

Apotech Research and Development Ltd.

Biogen Idcc Ma Inc.

Edimer Biotech S.a.

Apotech R&d S.a.

Pascal Schneider

Jurg Tschopp

Christine Ambrose

Jeffrey L Browning

Jeffrey Thompson

Fabienne MacKay

Christine Kowalczyk-Quintas

Olivier Gaide

Neil Kirby

Jürg Tschopp

Nathalie Dunkel

Stéphane Demotz

Paul David Rennert

Kenneth M Huttner

Bertrand Huard

Anh Thu Dang

Nils Holler

Christine Kowalczyk

Holm Schneider

Stephane Demotz

Fabienne Mackay

An antibody or a fragment thereof directed against an epitope including or being constituted by at least six contiguous amino acids in the SEQ ID NO: 1 or a conformational epitope comprising or being constituted by at least six amino acids of SEQ ID NO: 1 which are always in the order of the sequence, and its use for the prognosis and/or the diagnosis of a cancer.

Anti APRIL (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer

A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

Methods of modulating immune responses using BCMA polypeptide

The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.

Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein

The invention relates to methods for the intra-amniotic administration of EDA agonists, in particular EDI200. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with ectodermal dysplasias, in particular, XLHED.

Intra-amniotic administration of EDI200 for the treatment of ectodermal dysplasias

The present invention relates to the preparation of substantially purified anti-EDA1 monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as pharmaceutical compositions containing such antibodies. The antibodies may be used in the treatment of disorders relating to excessive action of EDA1 such as hirsutism, ectopic teeth, hyperhidrosis, breast cancer, dermal eccrine cylindroma or skin disorders such as sebaceous gland hyperplasia, comedones, milia, acne, seborrhea, rosacea, steatoma, and furuncles. The anti-EDA1 antibodies are also useful in immunoassays such as sandwich ELISA.

Anti-ectodysplasin antibodies

Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA)

Treatment of X-linked hypohidrotic ectodermal dysplasia with ectodysplasin A agonist

Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.

Pharmaceutical composition comprising EDA-1 Fusion Protein

Methods of screening for a compound that inhibits the interaction between BAFF and BCMA

The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.

Preparation of isolated agonist anti-EDAR monoclonal antibodies

Treatment of ectodermal dysplasia with EDA1 fusion proteins

Fusion constructs containing active sections on TNF ligands

The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. The oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.

Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins

Growing community of inventors

Epalinges, Switzerland

Pascal Schneider